L-Tryptophan side effects: what 425 FDA adverse event reports show

L-Tryptophan · Tryptophan · 19 reaction terms · 181 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Brand names

Tryptophan

openFDA label

Who reports

425 reports · 80% serious · 56 with death outcome · 70% female

openFDA FAERS counts, all years, deduplication not applied

Used for

For temporary relief of anxiety, bloating, constipation, mood swings, lethargy, inability to sleep and fatigue. Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 14 strongest signals

Reporting / coding artifact 4Lab value / disease marker 1No label text to screen 9

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 5 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Serotonin syndrome	29	74.9 52.7–106.5ROR 80.3 · χ² 2,040 / p <1e-300	71.4 EB05 52.2 · IC025 +4.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 54.3 · ♀ 48% (drug 70%)	no trial data cached
Product use complaint	18	57.4 36.5–90.2ROR 59.9 · χ² 941 / p 7e-207	54.2 EB05 36.3 · IC025 +3.7 3/3 methods agree	Reporting / coding artifact	serious n=17	no trial data cached
Taste disorder	18	44.4 28.2–69.7ROR 46.3 · χ² 720 / p 6e-159	42.5 EB05 28.4 · IC025 +3.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 64.1	no trial data cached
Blood calcium decreased	8	35.0 17.6–69.6ROR 35.7 · χ² 231 / p 2e-52	32.4 EB05 17.4 · IC025 +2.3 3/3 methods agree	Lab value / disease marker	serious PRR 31.5	no trial data cached
Rebound effect	8	34.8 17.5–69.2ROR 35.5 · χ² 230 / p 3e-52	32.2 EB05 17.3 · IC025 +2.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 40.3	no trial data cached
Inappropriate antidiuretic hormone secretion	7	33.9 16.3–70.8ROR 34.5 · χ² 192 / p 6e-44	31.0 EB05 15.8 · IC025 +2.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 24.6	no trial data cached
Personality change	5	26.4 11.0–63.1ROR 26.7 · χ² 98 / p 2e-23	22.3 EB05 7.5 · IC025 +1.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 25.5	no trial data cached
Akathisia (inner restlessness)	6	21.7 9.8–48.0ROR 22.0 · χ² 99 / p 1e-23	18.7 EB05 7.0 · IC025 +1.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 22.2	no trial data cached
Therapy partial responder	6	19.7 8.9–43.5ROR 19.9 · χ² 88 / p 3e-21	16.5 EB05 6.1 · IC025 +1.6 3/3 methods agree	Reporting / coding artifact	serious PRR 17.1	no trial data cached
Contraindicated product administered	12	19.6 11.2–34.3ROR 20.2 · χ² 194 / p 2e-44	18.7 EB05 10.8 · IC025 +2.5 3/3 methods agree	Reporting / coding artifact	serious PRR 16.1	no trial data cached
Disturbance in attention	21	19.2 12.6–29.1ROR 20.1 · χ² 344 / p 4e-77	18.8 EB05 12.8 · IC025 +3.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 20.6	no trial data cached
Sedation	8	15.1 7.6–30.1ROR 15.4 · χ² 92 / p 4e-22	12.8 EB05 5.7 · IC025 +1.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 15.0	no trial data cached
Withdrawal syndrome	7	8.2 3.9–17.1ROR 8.3 · χ² 37 / p 5e-10	5.8 EB05 2.9 · IC025 +1.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 6.1	no trial data cached
Drug abuse	10	5.9 3.2–10.9ROR 6.0 · χ² 36 / p 1e-9	4.8 EB05 2.8 · IC025 +1.2 3/3 methods agree	Reporting / coding artifact	serious PRR 4.3	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Serotonin syndrome	29	74.9 52.7–106.5ROR 80.3 · χ² 2,040 / p <1e-300	71.4 EB05 52.2 · IC025 +4.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 54.3 · ♀ 48% (drug 70%)	no trial data cached
Disturbance in attention	21	19.2 12.6–29.1ROR 20.1 · χ² 344 / p 4e-77	18.8 EB05 12.8 · IC025 +3.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 20.6	no trial data cached
Taste disorder	18	44.4 28.2–69.7ROR 46.3 · χ² 720 / p 6e-159	42.5 EB05 28.4 · IC025 +3.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 64.1	no trial data cached
Product use complaint	18	57.4 36.5–90.2ROR 59.9 · χ² 941 / p 7e-207	54.2 EB05 36.3 · IC025 +3.7 3/3 methods agree	Reporting / coding artifact	serious n=17	no trial data cached
Contraindicated product administered	12	19.6 11.2–34.3ROR 20.2 · χ² 194 / p 2e-44	18.7 EB05 10.8 · IC025 +2.5 3/3 methods agree	Reporting / coding artifact	serious PRR 16.1	no trial data cached
Drug abuse	10	5.9 3.2–10.9ROR 6.0 · χ² 36 / p 1e-9	4.8 EB05 2.8 · IC025 +1.2 3/3 methods agree	Reporting / coding artifact	serious PRR 4.3	no trial data cached
Sedation	8	15.1 7.6–30.1ROR 15.4 · χ² 92 / p 4e-22	12.8 EB05 5.7 · IC025 +1.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 15.0	no trial data cached
Rebound effect	8	34.8 17.5–69.2ROR 35.5 · χ² 230 / p 3e-52	32.2 EB05 17.3 · IC025 +2.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 40.3	no trial data cached
Blood calcium decreased	8	35.0 17.6–69.6ROR 35.7 · χ² 231 / p 2e-52	32.4 EB05 17.4 · IC025 +2.3 3/3 methods agree	Lab value / disease marker	serious PRR 31.5	no trial data cached
Withdrawal syndrome	7	8.2 3.9–17.1ROR 8.3 · χ² 37 / p 5e-10	5.8 EB05 2.9 · IC025 +1.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 6.1	no trial data cached
Inappropriate antidiuretic hormone secretion	7	33.9 16.3–70.8ROR 34.5 · χ² 192 / p 6e-44	31.0 EB05 15.8 · IC025 +2.1 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 24.6	no trial data cached
Therapy partial responder	6	19.7 8.9–43.5ROR 19.9 · χ² 88 / p 3e-21	16.5 EB05 6.1 · IC025 +1.6 3/3 methods agree	Reporting / coding artifact	serious PRR 17.1	no trial data cached
Akathisia (inner restlessness)	6	21.7 9.8–48.0ROR 22.0 · χ² 99 / p 1e-23	18.7 EB05 7.0 · IC025 +1.7 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 22.2	no trial data cached
Personality change	5	26.4 11.0–63.1ROR 26.7 · χ² 98 / p 2e-23	22.3 EB05 7.5 · IC025 +1.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 25.5	no trial data cached
Drug toxicity	4	14.3 5.4–37.9ROR 14.4 · χ² 37 / p 6e-10	8.7 EB05 2.8 · IC025 +0.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 10.7	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of L-Tryptophan?

In FDA FAERS, the most frequently co-reported reaction terms for L-Tryptophan are serotonin syndrome, disturbance in attention, taste disorder, sedation, rebound effect, blood calcium decreased. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does L-Tryptophan have an FDA boxed warning?

No. The FDA label retrieved for L-Tryptophan has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that L-Tryptophan causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 4f38c4e3-8ad6-4635-87fa-8253f1dc0e6b, effective 20260604; matched on openfda.generic_name.exact:"L-TRYPTOPHAN")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 19 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.